Muscular Dystrophy Improvement After Stem Cell Therapy in Mumbai India
He is a known case of MD with history of gradual onset of lower extremities muscle weakness noticed since age of 12 years with complaints of footwear slipping, frequent falling, difficulty in stairs climbing and getting up from floor. Gradually weakness progressed to upper extremities with difficulty in overhead activities. He even reports difficulty in pronunciation of "Ra", "La". He has no family history of MD. Functionally, he is modified independent in all ADL and mobility. On FIM he scores 79. After Stem Cell Treatment 1. Feels more energetic. Stamina has improved. 2. Sitting posture has improved. 3. Walking and standing posture is more erect. 4. Balance while walking has improved. 5. He can maintain kneeling position. 6. Bending and rotation from trunk is easier because of increase in back extensor strength. 7. Slow rate of speech achieved. 8. Lisping reduced. 9. Correct articulation for fricatives /s/, /sh/ and velar /ksha/ achieved in isolation. Stem Cell Therapy done at Dr Alok Shrama NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com

By: neurogenbsi

Continue reading here:
Muscular Dystrophy Improvement After Stem Cell Therapy in Mumbai India - Video

Inclusive Body Myopathy Improvement in Gujrati After Stem Cell Therapy in Mumbai India
He is a case of Inclusive Body Myopathy, since last 16 years with the history of slowness in running speed and slipping of "chappals" while walking and following foot drop. Weakness is progressive in nature and now involved muscles of all 4 limbs and trunk. Since last 3 years he is bedridden. Muscle biopsy is showing Inclusive Body Myopathy and EMG-NCV reports are showing generalized primary muscle disease. His elder sister also suffering from the same problem. Neurologically, he is hypotonic and hyporeflexic. On examination: he has grade 1+ muscle power in all 4 limbs proximally and grade 0 foot muscles and grade 3 distal muscles of upper limbs. Proximal muscle weakness is more than distal. Functionally, he is dependent in all ADL and mobility. On FIM he scores 48. After Stem Cell Treatment 1. Stamina has increased. 2. He can do suspension exercises for more range of motion and with more repetition without fatigue. 3. Now he can initiate rolling. He takes less support for rolling and turning. Earlier he used to change his position 4-5 times because of discomfort, but now he needs to change his position only once at night. 4. He can initiate supine to sit. 5. He is able to perform side lying to sitting by himself upto 70%. 6. Attempted drinking water in modified manner with right hand, which he couldn #39;t do before. Stem Cell Therapy done at Dr Alok Shrama NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur ...

By: neurogenbsi

More:
Inclusive Body Myopathy Improvement in Gujrati After Stem Cell Therapy in Mumbai India - Video

Published on 10 January 2013 Hits: 937 Written by Jovee Marie N. Dela Cruz

A HEALTH expert on Wednesday warned that stem cell therapy can also kill.

Dr. Leo Olarte, spokesman of the Philippine Society for Stem Cell Medicine, said that if the stem cell that a patient received is from a donor, it could lead to fatal complications.

He said that a stem cell transplant can pose risks of complications, some potentially fatal, depending on many factors including the type of blood disorder, the type of transplant and the age and health of the person.

Although some people experience few problems with a transplant, others may develop complications that may require treatment or hospitalization. Some complications could even be life-threatening, warned Olarte, also the vice chairman of the Philippine Medical Association.

He said that such complications could be in the form of graft-versus-host disease (allogeneic transplant only), stem cell (graft) failure, organ injury, infections, cataracts, infertility, new cancers and even death.

Olarte said that anyone undergoing a transplant using stem cells from a donor (allogeneic stem cell transplant) may be at risk of graft-versus-host disease.

This condition occurs when a donors transplanted stem cells attack your body. Graft-versus-host disease can be mild or severe. It can occur soon after your transplant or months to years later, he added.

The doctor said that incompatibility can also lead to diseases of the skin (rash, often like sunburn), gut (mouth sores, abdominal pain, diarrhea, nausea or vomiting), liver (jaundice or yellowing of the skin), lungs (blocked airways) or eyes (irritation and light sensitivity).

It can lead to chronic disability due to organ injury or infections and can be life-threatening. Your doctor must monitor closely for signs and symptoms of graft-versus-host disease, Olarte said.

Read the original:
Stem cell therapy can kill – health expert

Pioneers Stem Cell Therapy Poland veterinary dogs orthopedics, neurology, nefrology.wmv
Lubelskie Centrum Ma #322;ych Zwierz #261;t Using 10 years of knowledge in small animal Stem Cell Therapy in USA from one of the leading Referral Specialists Veterinary Clinic Pioneers of Stem Cell Therapy in Nefrology (with hemodialysis units) Orthopedics Neurology in Poland Any contact at komorkimacierzyste@lcmz.pl Each case is treated individually in terms of stem cell therapy. If there is any contraindication to the use of the therapy it wont be given.

By: MrLCMZ

See the rest here:
Pioneers Stem Cell Therapy Poland veterinary dogs orthopedics, neurology, nefrology.wmv - Video

Public release date: 11-Feb-2013 [ | E-mail | Share ]

Contact: Megan McCann memccann@nmh.org 312-926-5900 Northwestern Memorial Hospital

Each year, nearly 800,000 Americans suffer a stroke which can result in permanent brain damage, long term disability or death. As a leading cause of adult disability, stroke has an annual burden of more than $62 billion on the United States economy. With the exception of rehabilitation therapy, very few treatments are available to improve the chronic neurologic deficits caused by a stroke. In hopes of expanding therapeutic options, Northwestern Medicine researchers are investigating a novel stem cell therapy, known as SB623, that may hold the key to improving motor function following a disabling stroke.

Northwestern is currently one of only three sites in the nation enrolling participants in a landmark study to test the safety and efficacy of adult stem cell therapy for patients with stable ischemic stroke. Accounting for 87 percent of strokes, ischemic stroke occurs when a blocked artery interrupts the flow of oxygen and blood to the brain. This causes cell death and brain damage which can leave a person with impaired body functions, including paralysis, weakness on one side, difficulty with speech and language, vision issues, and cognitive challenges.

"Two million brain cells die each minute during a stroke making it critical to get treatment fast at the earliest sign of symptoms; once brain damage occurs, there's very little that can be done medically to reverse it," said principal investigator Joshua Rosenow, MD, director of Functional Neurosurgery at Northwestern Memorial Hospital and associate professor of neurosurgery, neurology, and physical medicine and rehabilitation at Northwestern University Feinberg School of Medicine. "While this study is only a preliminary step towards understanding the healing potential of these cells, we are excited about what a successful trial could do for a patient population that currently has very limited therapeutic options."

While the study's primary purpose is to examine the safety of SB623 stem cells, researchers will also seek to determine if the cells are effective in improving stroke symptoms. SB623 is derived from genetically engineered adult bone marrow cells from a healthy adult donor.

"Although not proven in humans, these stem cells have been shown to promote healing and improve function when administered in animal models of stable stroke," said co-investigator Richard Bernstein, MD, director of Northwestern Memorial's Stroke Center and associate professor of neurology at the Feinberg School. "The cells did not replace the neurons destroyed by stroke, but instead they appeared to encourage the brain to heal itself and promote the body's natural regenerative process. Eventually, the implanted stem cells disappeared."

"In this study, the cells are transplanted into the brain using brain mapping technology and scans, allowing us to precisely deposit the cells in the brain adjacent to the area damaged by stroke," explained Rosenow.

Early participants have received 2.5 million cells, but as the study progresses the dose will escalate to 5 million and eventually 10 million cells. Since SB623 cells are allogeneic, a single donor's cells can be used to treat many other individuals. Participants in the study will be followed for up to two years with periodic evaluations for safety and effectiveness in the improvement in motor function.

"Stroke can be a very disabling and life changing event," said Bernstein. "Even just a slight improvement in function could make a huge difference for a person impacted by stroke. To potentially give our patients the opportunity to permanently regain movement or speech is a very exciting prospect. In the animal models, the improvements appeared to remain even after the implanted stem cells disappeared."

Read more here:
Northwestern Medicine researchers investigate stem cell therapy for stroke

Stem Cell Therapy Testimonial - Arthritis Treatment (full version)
Stem Cell Therapy Testimonial - Arthritis Treatment (full version) 1-888-545-4333

By: Bofitmiami

View post:
Stem Cell Therapy Testimonial - Arthritis Treatment (full version) - Video

Stem Cell Therapy Testimonial - Hair loss treatment 1-888-545-4333
Stem Cell Therapy Testimonial - Hair loss treatment 1-888-545-4333

By: Bofitmiami

Excerpt from:
Stem Cell Therapy Testimonial - Hair loss treatment 1-888-545-4333 - Video

Stem Cell Therapy Testimonial - Arthritis 1-888-545-4333
Stem Cell Therapy Testimonial - Arthritis 1-888-545-4333

By: Bofitmiami

Read the original post:
Stem Cell Therapy Testimonial - Arthritis 1-888-545-4333 - Video

Dr.Omar Gonzalez Stem Cell Therapy Method
New Project 75

By: OmarGonzalezMD

See original here:
Dr.Omar Gonzalez Stem Cell Therapy Method - Video

Lady Receives Stemlogix Stem Cell Therapy
Lady received Stemlogix stem cell therapy to help with her severe arthritis in her hips! Watch Dr. Whalen, of LePar Animal Hospital in Evergreen Park, perform surgery and Stem Cell Therapy on Lady Bender, a 5 year old Mastiff with severe arthritis in the hips. Dr. Whalen has been treating her for severe arthritis since June of 2011. Lady #39;s condition was acute as she was not able to get up on her own. Lady was also overweight and gradually lost 20 lbs under Dr. Whalen #39;s care. The video also shows the process for Stem Cell Therapy, the collection and re-injection phase. Stem cells are harvested using the dog #39;s own fat tissue, then processed in-hospital and then re-injected into the joints that need it most. Concurrently to the Stem Cell treatment, Lady also undergoes cruciate ligament repair. Dr. Whalen is the first veterinarian in Illinois to perform stem cell therapy in-house. Video is courtesy of LePar Animal Hospital.

By: StemLogixLLC

Go here to see the original:
Lady Receives Stemlogix Stem Cell Therapy - Video

MANILA, Philippines --- The Department of Health (DOH) is preparing guidelines for the use of stem cell therapy in the treatment of diseases in the Philippines.

This was announced by DOH Secretary Enrique T. Ona yesterday in a convention on stem cell therapy at the Manila Hotel.

Ona said a bio-ethics advisory board will develop the guidelines which will include ethical standards in the application of stem cell therapy to treat diseases such as malignancies, blood disorders and metabolic disorders, among others.

"The institutional board will review and approve Stem Cell therapies based on guidelines by the advisory board," Ona said.

He added that the board will also include ethical and legal issues surrounding stem cell therapy.

Last week, the Philippine Medical Association (PMA) and the Philippine Society for Stem Cell Medicine (PSSCM) issued a joint statement that warned against the dangers of receiving stem cell transplants that came from another source other than the patient's body.

"If the stem cell that you received is not from your own body, it could lead to fatal complications," Philippine Society for Stem Cell Medicine (PSSCM) and the PMA said.

The doctors warned that complications arising from stem cell transplants include graft-versus-host disease, stem cell (graft) failure, organ injury, infections, cataracts, infertility, new cancers, and even death.

Ona said a public hearing will be held on January 18 regarding the preliminary draft of the guidelines.

He said the guidelines will ensure the minimum quality of service and application in the use of stem cells in health settings.

See the original post:
Stem Cell Therapy Guidelines Readied

AUSTIN, Texas, Jan. 8, 2013 /PRNewswire/ --On Friday, January 4th Celling Biosciences hosted the Austin Cell Therapy Symposium at the downtown Hilton to build awareness and provide a platform for physicians, scientists, policy makers and academia to discuss the impact of cell therapy on global healthcare and the opportunity for the local community in Central Texas. Cell therapy will revolutionize the landscape of medicine by providing viable and affordable treatment options across all disciplines of medicine without the controversy associated with embryonic stem cells.

The keynote speaker for the event was Dr. Arnold I. Caplan, Professor of Biology and Director of the Skeletal Research Center at Case Western Reserve University. Dr. Caplan has published over 390 papers and manuscripts and has long been supported by the National Institute of Health and other non-profit and for-profit agencies for his efforts in trying to understand the development, maturation and aging of cartilage, bone, skin and other mesenchymal cell tissues."I firmly believe that the research and development efforts going on today will change the future of medicine forever. We are only scratching the surface of the potential there is to treat different health issues with cell therapy. It takes a concerted effort by scientists, physicians and commercial entities for patients to ultimately enjoy the benefits. This type of platform provided by Celling Biosciences allows us to effectively progress forward," says Dr. Caplan.

Dr. Carl Gregory from the Texas A&M Regenerative Medicine Institute and Dr. Vivienne Rebel from UT Health Science Center San Antonio both represented local academia in Central Texas. The research being conducted and the recruitment of students trained in these programs are obvious reasons for Texans to keep supporting Governor Perry's efforts to make Texas a leader in the research and commercialization efforts of regenerative cell therapy. Both speakers are leading efforts for research that will one day lead to alternative healthcare options.

Dr. Philippe Hernigou, a leading orthopedic surgeon from France, presented his 20 years clinical experience working with cell therapy in his practice as University of Paris Chief of Orthopedics.Dr. Hernigou is well published in his clinical use of cell therapy and has treated over 2,500 patients utilizing autologous bone marrow derived cells to treat a wide range of orthopedic pathologies. Dr. Hernigou's research on the safety of cell therapy has been accepted and will be presented at the 2013 AAOS, a leading congress for orthopedic surgeons.

Clinicians were also represented by Dr. Scott Spann, an orthopedic surgeon at Westlake Hospital in Austin, who provides care to patients with spinal cord injury.Dr. Spann believes one day cell therapy will be a common option for patients suffering from debilitating health issues like spinal cord injury.A member of the audience and orthopedic surgeon, Dr. Christoph Meyer has been utilizing cell therapy in his practice for years and also believes it is the future of medicine. "Thanks to these efforts, physicians are benefiting from access to the growing body of research based medicine being established in the field of cellular therapy and regenerative medicine.As the technology is developed, it ultimately gives my patients the best care available and this event gives me the opportunity to discuss experiences with world leaders in cell therapy."

Healthcare is going through major changes and cell therapy is going to have many challenges ahead. Julian Rivera, legal healthcare specialist at the Brown McCarroll Law Firm, discussed the impact of the recent challenges in front of the Texas Medical Board which has adopted rules that work with the FDA to help keep Texas revolutionizing cell therapy.Mr. Rivera believes that the legal issues will take time but is optimistic about how the State of Texas has handled the challenges thus far.

"We are fortunate to have industry leaders joining us to discuss the future impact of cell therapy. We are proud to be Texans who are pioneering the way in the global healthcare market place for regenerative cell therapies. Celling Biosciences understands that the cell therapy market is in its infancy which is a key reason why we invest heavily on research and development with our teams of scientists, engineers and registered nurses providing physicians with proven cell centric technologies and techniques that collectively help to recreate the human body's biological environment. It is not about just providing cells to treat patients.We believe with the help of these thought leaders presenting today we will get closer to better understanding how to keep delivering safe, efficacious and cost effective therapies to patients," says Founder and CEO of Celling Biosciences, Kevin Dunworth.

About Celling BiosciencesCelling Biosciences is an Austin based company working closely with world leaders in academia, medicine, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine.Celling's product-offering focuses on autologous adult stem cell therapy and the devices and services that compliment these procedures.For more information please visit: http://www.cellingbiosciences.com.

Read more:
Celling Biosciences Hosts Austin Cell Therapy Symposium

Stem Cell Therapy for Autism, Mumbai, India

By: Rajeev Ranjan

View original post here:
Stem Cell Therapy for Autism, Mumbai, India - Video

Centagen has developed a breakthrough stem cell therapy that rejuvenates a patient's own adult stem cells. The Company has found a way to expand a patients own stem cells in the lab millions of times while rejuvenating the cells. For example, a patients blood pleuropotent stem cells could be rejuvenated and expanded in the lab and then re-injected to repair and rejuvenate organs and tissues damaged by aging or disease. Centagen has announced a funding campaign at http://www.indiegogo.com/centagen for additonal research and development.

Boulder, Colorado (PRWEB) December 31, 2012

Each of us has a limited supply of the kind of stem cells needed to rebuild, repair, and rejuvenate any part of our body. As we age, the supply and healing power of our stem cells diminishes. By providing a practically unlimited supply of one's own rejuvenated stem cells, we may keep people young and healthy for well over a century. In particular, regenerating tissues and organs prepared by expanding ones own stem cells could help with Alzheimers disease, diabetes, immune senescence, damaged heart tissue, arteriosclerosis, failing kidneys, failing hearing or eyesight, osteoporosis, weak muscles, and aged skin.

The technology requires no genetic engineering of the stem cells, so the procedure is much safer than the current procedures requiring genetic tampering. Only a patients adult stem cells are used, so there are no ethical issues common with embryonic stem cell use or side effects due to tissue rejection by your immune system.

Centagen has recently opened a crowd funding bid at http://www.indiegogo.com/centagen in concert with Maximum Life foundation, whose mission is to make 100 years old the new 50.

Forward-Looking Statements for Centagen, Inc.

This press release contains several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy of stem cell therapeutics. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors and the Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control. The Company may not update these forward-looking statements in a timely manner as conditions change.

Bryant Villeponteau, Ph.D. Centagen (877) 757-1923 Email Information

Link:
Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.

Marie Csete of AABB on AABB accreditation - at World Cord Blood Congress 2012
Marie Csete, Director of Cell Therapy at AABB, spoke at the World Cord Blood Congress 2012 on the topic, #39;AABB accreditation: a global approach to collaboration, innovation and quality. #39; World Cord Blood Congress is where private and public cord blood banks, pharma and biotechs, academia and government come to debate advances in cord blood banking and therapeutics. For more information, go to http://www.terrapinn.com/cordblood. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:21:41More inScience Technology

See original here:
Marie Csete of AABB on AABB accreditation - at World Cord Blood Congress 2012 - Video

Stem Cell Therapy at Integra Medical Center IMC
New Project 64From:OmarGonzalezMDViews:0 0ratingsTime:06:12More inScience Technology

Go here to read the rest:
Stem Cell Therapy at Integra Medical Center IMC - Video

Donna Skerrett of Mesoblast on adult stem cell therapies - at Stem Cells USA RM Congress 2012
Donna Skerrett, Chief Medical Officer of Mesoblast, presented a case study on Mesoblast and their adult stem cell therapy at the Stem Cells USA Regenerative Medicine Congress 2012. The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:21:30More inScience Technology

Go here to see the original:
Donna Skerrett of Mesoblast on adult stem cell therapies - at Stem Cells USA

Live Cell Therapy | Stem Cell Malaysia
stemcellmalaysia.com Live cell therapy is one form of stem cell therapy under the hierarchy of cell therapy, which is under regenerative medicine. Live cell therapy was made popular since 1931 by Dr Paul Niehans, who pioneered the therapy using injection. Oral or injection live cell therapy is far more superior than surgical implantation due to several advantages. Today, live cell therapy has been applied to disease treatment, beauty and health rejuvenation. For more information on stem cell therapy, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:172 10ratingsTime:12:14More inScience Technology

See the original post:
Live Cell Therapy | Stem Cell Malaysia - Video

ScienceDaily (Nov. 27, 2012) A new method of growing cardiac tissue is teaching old stem cells new tricks. The discovery, which transforms aged stem cells into cells that function like much younger ones, may one day enable scientists to grow cardiac patches for damaged or diseased hearts from a patient's own stem cells -- no matter what age the patient -- while avoiding the threat of rejection.

Stem cell therapies involving donated bone marrow stem cells run the risk of patient rejection in a portion of the population, argues Milica Radisic, Canada Research Chair in Functional Cardiovascular Tissue Engineering at the Institute of Biomaterials and Biomedical Engineering (IBBME) and Associate Professor in the Department of Chemical Engineering and Applied Chemistry at the University of Toronto.

One method of avoiding the risk of rejection has been to use cells derived from a patient's own body. But until now, clinical trials of this kind of therapy using elderly patients' own cells have not been a viable option, since aged cells tend not to function as well as cells from young patients.

"If you want to treat these people with their own cells, how do you do this?"

It's a problem that Radisic and her co-researcher, Dr. Ren-Ke Li, think they might have an answer for: by creating the conditions for a 'fountain of youth' reaction within a tissue culture.

Li holds the Canada Research Chair in Cardiac Regeneration and is a Professor in the Division of Cardiovascular Surgery, cross-appointed to IBBME. He is also a Senior Scientist at the Toronto General Research Institute.

Radisic and Li first create a "micro-environment" that allows heart tissue to grow, with stem cells donated from elderly patients at the Toronto General Hospital.

The cell cultures are then infused with a combination of growth factors -- common factors that cause blood vessel growth and cell proliferation -- positioned in such a way within the porous scaffolding that the cells are able to be stimulated by these factors.

Dr. Li and his team then tracked the molecular changes in the tissue patch cells. "We saw certain aging factors turned off," states Li, citing the levels of two molecules in particular, p16 and RGN, which effectively turned back the clock in the cells, returning them to robust and healthy states.

"It's very exciting research," says Radisic, who was named one of the top innovators under 35 by MIT in 2008 and winner of the 2012 Young Engineers Canada award.

Read more:
'Fountain of youth' technique rejuvenates aging stem cells

SCMOM 2012_Stanford Cardiovascular Institute
Stanford Cardiovascular Institute (CVI) is the nucleus for cardiovascular research at Stanford University. Formed in 2004, the Cardiovascular Institute is home to Stanford #39;s myriad cardiovascular-related adult and pediatric research, clinical, and educational programs, centers and laboratories, as well as over 500 Stanford basic scientists, graduate students, clinician scientists, and other researchers in heart and vessel disease and prevention. Within the area of cardiac regenerative medicine, the Stanford CVI has significant research endeavors involving human pluripotent stem cells for (1) cardiovascular disease modeling, (2) drug screening and discovery, and (3) personalized cell therapy. Recently, Stanford CVI investigators received a $20 million CIRM Disease Team Therapy Award for performing pre-IND work that would enable the first-in-man clinical trial involving injection of human embryonic stem cell-derived cardiomyocytes for patients with heart failure. wulab.stanford.edu Presenter Joseph Wu, Associate Professor, Cardiovascular Medicine, Stanford University School of MedicineFrom:AllianceRegenMedViews:3 0ratingsTime:17:06More inScience Technology

Original post:
SCMOM 2012_Stanford Cardiovascular Institute - Video